Development and validation of the trans-omics model for pancreatic adenocarcinoma

Epigenomics. 2021 Jan;13(1):15-30. doi: 10.2217/epi-2020-0184. Epub 2020 Dec 24.

Abstract

Aim: To develop a trans-omics-based molecular clinicopathological algorithm for predicting pancreatic adenocarcinoma prognosis, we performed a comprehensive analysis of the expression levels of mRNA, DNA methylation and DNA copy number in The Cancer Genome Atlas dataset. Materials & methods: Based on the least absolute shrinkage and selection operator method - COX regression analysis, a trans-omics-based classifier was established to predict overall survival. Nomogram was constructed by combining the classifier band clinical pathological characterization. Results: Based on trans-omics, we developed a 10-gene-based classifier and a molecular-clinicopathologic nomogram for predicting overall survival with satisfactory accuracy. Conclusion: Trans-omics-based classifier and molecule-clinicopathological nomogram based on the classifier can accurately predict the prognosis of pancreatic adenocarcinoma patients.

Keywords: DNA methylation; The Cancer Genome Atlas; copy number variation; interchromosomal gene conversion; pancreatic adenocarcinoma; trans-omics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / genetics*
  • Adenocarcinoma / pathology
  • Aged
  • Algorithms
  • DNA Copy Number Variations / genetics
  • DNA Methylation / genetics
  • Female
  • Gene Expression
  • Humans
  • Male
  • Middle Aged
  • Models, Genetic*
  • Nomograms
  • Pancreatic Neoplasms / genetics*
  • Pancreatic Neoplasms / pathology
  • Prognosis
  • RNA, Messenger / genetics
  • Reproducibility of Results

Substances

  • RNA, Messenger